KR20250009587A - 전환 성장 인자-β1에 높은 친화성, 결합력 및 특이성으로 결합하는 ｓｃＦｖ-Ｆｃ 이량체 - Google Patents

전환 성장 인자-β1에 높은 친화성, 결합력 및 특이성으로 결합하는 ｓｃＦｖ-Ｆｃ 이량체 Download PDF

Info

Publication number
KR20250009587A
KR20250009587A KR1020257000711A KR20257000711A KR20250009587A KR 20250009587 A KR20250009587 A KR 20250009587A KR 1020257000711 A KR1020257000711 A KR 1020257000711A KR 20257000711 A KR20257000711 A KR 20257000711A KR 20250009587 A KR20250009587 A KR 20250009587A
Authority
KR
South Korea
Prior art keywords
ser
gly
leu
thr
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257000711A
Other languages
English (en)
Korean (ko)
Inventor
화웨이 추
클라크 팬
줄리 버드
Original Assignee
젠자임 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 젠자임 코포레이션 filed Critical 젠자임 코포레이션
Publication of KR20250009587A publication Critical patent/KR20250009587A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020257000711A 2015-03-04 2016-03-03 전환 성장 인자-β1에 높은 친화성, 결합력 및 특이성으로 결합하는 ｓｃＦｖ-Ｆｃ 이량체 Pending KR20250009587A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562128133P 2015-03-04 2015-03-04
US62/128,133 2015-03-04
KR1020237037758A KR102754133B1 (ko) 2015-03-04 2016-03-03 전환 성장 인자-β1에 높은 친화성, 결합력 및 특이성으로 결합하는 ｓｃＦｖ-Ｆｃ 이량체
PCT/US2016/020779 WO2016141244A1 (en) 2015-03-04 2016-03-03 scFv-Fc DIMERS THAT BIND TRASFORMING GROWTH FACTOR-β1 WITH HIGH AFFINITY, AVIDITY AND SPECIFICITY

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020237037758A Division KR102754133B1 (ko) 2015-03-04 2016-03-03 전환 성장 인자-β1에 높은 친화성, 결합력 및 특이성으로 결합하는 ｓｃＦｖ-Ｆｃ 이량체

Publications (1)

Publication Number Publication Date
KR20250009587A true KR20250009587A (ko) 2025-01-17

Family

ID=55538640

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020257000711A Pending KR20250009587A (ko) 2015-03-04 2016-03-03 전환 성장 인자-β1에 높은 친화성, 결합력 및 특이성으로 결합하는 ｓｃＦｖ-Ｆｃ 이량체
KR1020237037758A Active KR102754133B1 (ko) 2015-03-04 2016-03-03 전환 성장 인자-β1에 높은 친화성, 결합력 및 특이성으로 결합하는 ｓｃＦｖ-Ｆｃ 이량체
KR1020177027371A Active KR102598790B1 (ko) 2015-03-04 2016-03-03 전환 성장 인자-β1에 높은 친화성, 결합력 및 특이성으로 결합하는 ｓｃＦｖ-Ｆｃ 이량체

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020237037758A Active KR102754133B1 (ko) 2015-03-04 2016-03-03 전환 성장 인자-β1에 높은 친화성, 결합력 및 특이성으로 결합하는 ｓｃＦｖ-Ｆｃ 이량체
KR1020177027371A Active KR102598790B1 (ko) 2015-03-04 2016-03-03 전환 성장 인자-β1에 높은 친화성, 결합력 및 특이성으로 결합하는 ｓｃＦｖ-Ｆｃ 이량체

Country Status (15)

Country Link
US (4) US10508146B2 (https=)
EP (2) EP4527850A3 (https=)
JP (1) JP6845802B2 (https=)
KR (3) KR20250009587A (https=)
CN (1) CN107889491B (https=)
AR (1) AR103839A1 (https=)
AU (1) AU2016226097B2 (https=)
BR (1) BR112017018767A2 (https=)
ES (1) ES3014555T3 (https=)
IL (1) IL254238B (https=)
MX (2) MX2017011251A (https=)
RU (1) RU2733286C2 (https=)
SG (2) SG10201912449UA (https=)
TW (1) TWI726870B (https=)
WO (1) WO2016141244A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI733661B (zh) 2015-03-04 2021-07-21 美商健臻公司 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體
TWI726870B (zh) 2015-03-04 2021-05-11 美商健臻公司 具有高親和性、結合性及專一性之結合轉形生長因子-β１的ｓｃＦｖ-Ｆｃ二聚體
EP3448987A4 (en) 2016-04-29 2020-05-27 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
US20220119513A1 (en) * 2020-06-08 2022-04-21 Zoetis Services Llc Anti-tgfb antibodies and therapeutic uses thereof
CN112500491B (zh) * 2020-12-18 2022-04-08 深圳市迈加瑞生物技术有限公司 一种特异性中和辅助性T细胞TGF-β信号的双特异性抗体、其药物组合及其用途
CN116179493A (zh) * 2021-09-29 2023-05-30 成都美杰赛尔生物科技有限公司 敲除两种免疫检测点基因的免疫细胞及其制备方法与应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020099179A1 (en) 1989-12-21 2002-07-25 Linda K. Jolliffe Cdr-grafted antibodies
US5616561A (en) 1995-03-31 1997-04-01 Regents Of The University Of California TGF-β antagonists as mitigators of radiation-induced tissue damage
ES2146552B1 (es) * 1998-11-24 2001-04-16 Inst Cientifico Tecnol Navarra Peptidos inhibidores de tgf/31
EP1486560A3 (en) 1999-04-30 2005-02-09 Cambridge Antibody Technology LTD Specific antibodies and antibody fragments for TGFBETA1
US6492497B1 (en) 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
EP1620128A1 (en) 2003-04-30 2006-02-01 Genzyme Corporation Tgf-beta antagonists combined with renin-angiotensin-aldosteron-system antagonists for treating renal insufficiency
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
CN101084007A (zh) 2004-09-22 2007-12-05 金齐姆公司 TGF－β拮抗剂限制免疫抑制剂肾毒性的用途
US9284375B2 (en) * 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
ATE505489T1 (de) * 2005-04-22 2011-04-15 Lilly Co Eli Tgf-beta-1-spezifische antikörper
JP2009521496A (ja) 2005-12-23 2009-06-04 イーライ リリー アンド カンパニー ＴＧＦ−β結合組成物
KR101516823B1 (ko) 2006-03-17 2015-05-07 바이오겐 아이덱 엠에이 인코포레이티드 안정화된 폴리펩티드 조성물
CA2644663A1 (en) 2006-03-23 2007-09-27 Kirin Pharma Kabushiki Kaisha Agonist antibody to human thrombopoietin receptor
DK2083863T3 (da) 2006-10-03 2015-06-22 Genzyme Corp Antistoffer mod tgf-beta til anvendelse til behandling af spædbørn med risiko for udvikling af bronkopulmonal dysplasi
EA019512B1 (ru) 2008-07-02 2014-04-30 Эмерджент Продакт Дивелопмент Сиэтл, Ллс Il-6-опосредованная иммунотерапия
US20120294868A1 (en) 2009-04-24 2012-11-22 Edwards James R Anti-tgf-beta induction of bone cell function and bone growth
US9409950B2 (en) * 2010-12-23 2016-08-09 Biogen Ma Inc. Linker peptides and polypeptides comprising same
TWI588156B (zh) 2011-03-28 2017-06-21 賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
SG195253A1 (en) 2011-06-03 2013-12-30 Xoma Technology Ltd Antibodies specific for tgf-beta
US20140072581A1 (en) 2012-07-23 2014-03-13 Zymeworks Inc. Immunoglobulin Constructs Comprising Selective Pairing of the Light and Heavy Chains
PT2971048T (pt) 2013-03-11 2019-02-06 Genzyme Corp Anticorpos anti-tgf-beta manipulados e fragmentos de ligação a antigénios
HUE046702T2 (hu) 2013-03-20 2020-03-30 Genzyme Corp Eljárások üvegcsontbetegség kezelésére
TWI726870B (zh) 2015-03-04 2021-05-11 美商健臻公司 具有高親和性、結合性及專一性之結合轉形生長因子-β１的ｓｃＦｖ-Ｆｃ二聚體
TWI733661B (zh) 2015-03-04 2021-07-21 美商健臻公司 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體

Also Published As

Publication number Publication date
US20240343790A1 (en) 2024-10-17
ES3014555T3 (en) 2025-04-23
MX2017011251A (es) 2018-02-19
MX2022007456A (es) 2022-06-27
US11976112B2 (en) 2024-05-07
KR20170120173A (ko) 2017-10-30
US20200131258A1 (en) 2020-04-30
IL254238B (en) 2022-01-01
RU2733286C2 (ru) 2020-10-01
SG11201707105TA (en) 2017-09-28
AU2016226097A8 (en) 2017-11-09
AU2016226097B2 (en) 2022-01-13
CN107889491A (zh) 2018-04-06
SG10201912449UA (en) 2020-02-27
WO2016141244A8 (en) 2016-10-20
IL254238A0 (en) 2017-10-31
RU2017134042A3 (https=) 2019-10-08
JP2018508218A (ja) 2018-03-29
US11325971B2 (en) 2022-05-10
WO2016141244A1 (en) 2016-09-09
JP6845802B2 (ja) 2021-03-24
CN107889491B (zh) 2022-01-07
RU2017134042A (ru) 2019-04-05
TWI726870B (zh) 2021-05-11
KR20230156798A (ko) 2023-11-14
CA2978459A1 (en) 2016-09-09
US20180222970A1 (en) 2018-08-09
US12473356B2 (en) 2025-11-18
EP3265484C0 (en) 2024-12-25
EP3265484B1 (en) 2024-12-25
BR112017018767A2 (pt) 2018-04-17
EP4527850A3 (en) 2025-06-04
AR103839A1 (es) 2017-06-07
KR102598790B1 (ko) 2023-11-07
US20220363740A1 (en) 2022-11-17
AU2016226097A1 (en) 2017-10-26
US10508146B2 (en) 2019-12-17
KR102754133B1 (ko) 2025-01-15
EP4527850A2 (en) 2025-03-26
TW201706303A (zh) 2017-02-16
EP3265484A1 (en) 2018-01-10

Similar Documents

Publication Publication Date Title
KR102754133B1 (ko) 전환 성장 인자-β1에 높은 친화성, 결합력 및 특이성으로 결합하는 ｓｃＦｖ-Ｆｃ 이량체
RU2681502C2 (ru) Сконструированные анти-tgf-бета антитела и антиген-связывающие фрагменты
TWI733661B (zh) 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體
CN114853890B (zh) 一种prlr抗原结合蛋白及其制备方法和应用
CN112175087B (zh) 一种抗CD4和TGFβ的双特异性抗体、其药物组合及其用途
AU2021403263B2 (en) Bispecific antibody for specifically neutralizing tgf-β signal of helper t cell, and pharmaceutical combination and use thereof
HK40117203A (en) Scfv-fc dimers that bind transforming growth factor-beta1 with high affinity, avidity and specificity
BR112017018678B1 (pt) Proteína de ligação isolada que liga tgf?1, seu método de preparo e seu uso, composição farmacêutica, polinucleotídeo isolado e vetor de expressão de mamífero

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20250108

Application number text: 1020237037758

Filing date: 20231101

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250207

Comment text: Request for Examination of Application